An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Trending
- Will Brooklyn regret launching a grenade at Brand Beckham? | Ents & Arts News
- Syrian government forces advance in northeast as Kurds vow to resist
- ‘We prefer respect to bullies,’ Macron says
- Are ‘tech dense’ farms the future of farming?
- Tumor zo groot als een tennisbal zette het leven van Melanie (37) wéér op z’n kop
- ‘A never-ending queue’ – hospitals where waits are getting worse
- M&S technology chief quits less than a year after cyber attack | Money News
- Wage growth slows as number of people employed falls
